Polyarteritis Nodosa: ['A necrotizing vasculitis that affects medium-sized arteries, it is usually idiopathic, and may be triggered by viral infections (Hepatitis B, also others). A multisystem disease, it most commonly affects skin (nodules, livedo reticularis) and peripheral nerves; higher morbidity is associated with gastrointestinal, central nervous system, cardiac, and/or other organ involvement. Anti-neutrophil cytoplasmic antibodies (ANCA) are typically negative. [ NCI ]']
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
98 |
4. Check minimum number of eventsNone |
98 |
5. Include endpointsNone |
98 |
6. Filter based on genotype QC (FinnGen only) |
87 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30
- Name in latin
- Aliae condiciones polyarteritidi nodosae cognatae
Similar endpoints
↥List of similar endpoints to
Other conditions related to polyarteritis nodosa
based on the number of shared cases.
Similar with more cases:
- Polyarteritis nodosa and related conditions
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 581 | 336 | 240 |
| Only index persons | 484 | 287 | 197 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 64.23 | 64.19 | 64.15 |
| Only index persons | 62.10 | 63.01 | 60.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 87 | 56 | 31 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 57.91 | 54.61 | 63.87 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 91
- Matched controls
- 910
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M30.8
ICD-10 Finland
Other conditions related to polyarteritis nodosa
+∞
125.5
89
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
9.9
23.7
35
54
H02AB06
ATC
prednisolone; systemic
15.7
23.4
82
333
L04AX01
ATC
azathioprine; systemic
27.7
21.3
29
15
M30.0
ICD-10 Finland
Polyarteritis nodosa
+∞
20.6
19
*
L04AX03
ATC
methotrexate; systemic
8.2
17.2
28
47
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.9
15.7
60
224
M05BA04
ATC
alendronic acid; oral
8.2
15.4
24
38
H02AB07
ATC
prednisone; oral
5.8
11.6
26
59
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.0
11.5
21
22
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.5
10.3
64
315
ZX120
NOMESCO Finland
Intravenous
5.0
9.0
23
58
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.9
8.9
39
148
TGC00
NOMESCO Finland
Bronchial lavation
16.6
8.5
13
9
M31.9
ICD-10 Finland
Necrotizing vasculopathy, unspecified
+∞
8.5
8
*
M31.7
ICD-10 Finland
Microscopic polyangiitis
+∞
8.5
8
*
M30.1
ICD-10 Finland
Polyarteritis with lung involvement [Churg-Strauss]
+∞
8.5
8
*
PAW37
NOMESCO Finland
Biopsy of temporal artery
+∞
8.5
8
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.3
8.3
18
26
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.5
8.1
19
31
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
7.0
7.8
19
33
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.5
7.7
22
60
N03AX16
ATC
[U] pregabalin
3.5
7.6
37
148
D69.0
ICD-10 Finland
Allergic purpura
86.9
7.5
8
*
H02AB09
ATC
hydrocortisone; systemic
13.6
7.3
12
10
L04AA06
ATC
mycophenolic acid; systemic
32.9
7.3
9
*
H02AB04
ATC
methylprednisolone; systemic
3.9
7.0
25
81
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.6
6.9
28
99
Z01.8
ICD-10 Finland
Other specified special examinations
3.5
6.6
29
107
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
74.9
6.5
7
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
74.9
6.5
7
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.7
6.5
16
28
L95.9
ICD-10 Finland
Vasculitis limited to skin, unspecified
+∞
6.3
6
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
6.3
6
*
R03BB04
ATC
tiotropium bromide; inhalant
4.4
6.1
17
45
SPAT1301
SPAT
No procedures
3.0
6.1
40
187
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
25
9
37.56
20.03
2.8
1.1
532.50
—
titre
—
8
0
24
14
22.74
16.75
10.7
1.3
14.89
—
iu/ml
—
8
0
24
26
12.11
13.01
3.7
1.2
7.54
8.97
iu/ml
—
7
6
60
273
4.52
11.04
7.3
3.2
—
—
—
0
0
15
11
16.02
9.58
1.6
1.2
—
—
—
0
0
16
15
12.66
9.23
1.3
1.2
—
—
—
0
0
27
79
4.44
8.77
3.1
2.1
260.96
407.56
nmol/l
3.19
27
70
13
11
13.54
7.86
1.2
2.3
—
—
—
0
0
67
389
3.74
7.49
9.1
8.7
1.21
1.21
mmol/l
0.00
55
344
35
137
3.53
7.42
2.5
1.8
—
—
—
0
0
59
323
3.35
7.13
8.3
3.8
24.39
42.63
ng/l
0.78
48
223
13
14
10.61
7.06
1.2
2.1
—
—
—
0
0
62
351
3.40
7.06
4.0
2.3
89.42
75.68
nmol/l
3.35
57
320
19
51
4.44
6.78
6.1
5.3
1.23
1.22
mmol/l
0.33
19
45
9
5
19.72
6.40
1.3
2.0
—
—
—
0
0
12
14
9.67
6.28
2.3
1.4
—
—
—
0
0
37
164
3.12
6.25
1.7
1.6
1.12
1.08
mg/l
0.06
30
134
45
223
3.01
6.24
7.5
3.0
0.11
0.41
e6/l
2.01
39
163
13
18
8.22
6.18
1.2
1.8
—
—
—
0
0
14
22
7.31
6.14
1.4
1.6
—
—
—
0
0
12
15
9.02
6.06
1.3
1.8
—
—
—
0
0
9
6
16.43
6.04
1.7
1.7
—
—
—
0
0
17
36
5.56
5.99
1.9
2.9
1.35
2.04
mmol/l
0.25
12
28
11
12
10.24
5.98
1.5
1.9
—
—
—
0
0
14
23
6.99
5.97
1.4
1.7
—
—
—
0
0
11
13
9.44
5.74
1.5
1.6
—
—
—
0
0
26
102
3.17
5.30
2.1
1.7
—
—
—
0
0
70
473
3.08
5.05
5.8
6.5
6.92
6.70
mmol/l
0.18
70
447
14
30
5.32
4.93
1.8
3.3
—
—
—
0
0
9
10
9.83
4.90
1.7
1.4
—
—
—
0
0
47
264
2.61
4.83
7.0
3.6
0.00
0.00
estimate
-0.00
28
82
9
11
8.93
4.68
1.2
1.3
—
—
—
0
0
39
208
2.53
4.37
3.3
2.7
334.36
341.59
umol/l
0.12
33
176
12
28
4.77
3.99
1.8
2.3
1.27
1.53
mg/l
0.68
12
23
11
24
5.06
3.89
1.4
2.5
243.19
503.80
ug/l
0.49
11
24
24
106
2.72
3.88
2.1
1.6
—
—
—
0
0
7
8
9.35
3.84
1.3
1.1
—
—
—
0
0
65
456
2.49
3.79
7.7
3.6
0.00
0.00
estimate
-0.00
30
93
28
138
2.49
3.61
1.4
1.2
29.45
21.15
u/ml
0.15
13
47
30
154
2.41
3.54
1.6
1.2
36.66
41.36
iu/ml
0.09
13
47
63
448
2.32
3.38
7.9
3.6
0.00
0.00
estimate
-0.00
28
92
64
459
2.33
3.35
7.8
3.6
0.00
0.00
estimate
-0.00
28
90
20
88
2.63
3.22
4.5
3.4
—
—
—
0
0
5
5
10.47
3.01
1.2
1.0
—
—
—
0
0
7
14
5.32
2.78
2.1
3.1
5.77
11.84
pmol/l
—
7
14
5
6
8.72
2.78
1.0
1.2
249.80
251.50
mg/l
—
5
6
15
63
2.65
2.62
1.9
11.5
1.40
1.13
mmol/l
0.81
15
63
11
37
3.24
2.59
2.7
1.6
—
—
—
0
0
6
11
5.75
2.58
9.7
3.1
—
—
—
0
0
24
127
2.21
2.57
7.1
3.0
3.24
3.60
e6/l
0.06
14
70
9
27
3.58
2.47
1.7
2.2
25.24
24.86
mmol/l
—
9
27
5
8
6.53
2.40
1.0
1.3
—
—
—
0
0
15
66
2.52
2.40
2.5
1.5
—
—
—
0
0
12
47
2.79
2.38
3.2
10.4
23.98
25.27
mmol/l
0.75
12
47
13
54
2.64
2.32
3.8
3.0
73.92
68.15
ng/l
0.10
13
47
7
18
4.12
2.30
2.4
1.6
—
—
—
0
0
39
258
1.90
2.25
6.8
3.1
0.00
0.01
estimate
0.49
21
73
5
9
5.80
2.24
2.4
4.7
2.60
0.44
%
—
5
9
9
30
3.21
2.21
1.7
1.4
—
—
—
0
0
6
15
4.20
2.07
1.5
1.4
—
—
—
0
0
6
15
4.20
2.07
1.5
1.4
—
—
—
0
0
20
111
2.03
1.87
2.6
9.2
103.75
104.34
mmol/l
0.20
20
111
32
210
1.81
1.83
3.7
2.1
3.62
2.82
mg/l
1.34
27
180
23
136
1.92
1.81
7.2
2.9
0.43
1.03
e6/l
0.85
13
76
6
19
3.30
1.69
1.7
1.6
—
—
—
0
0
47
353
1.69
1.64
7.6
3.6
0.00
0.01
estimate
0.49
25
80
53
638
0.59
1.57
48.4
21.2
328.87
331.43
g/l
0.96
53
638
5
15
3.46
1.54
1.0
1.9
—
—
—
0
0
33
234
1.64
1.39
1.8
1.7
20.76
20.97
nmol/l
0.03
27
197
6
23
2.72
1.39
1.8
2.3
134.67
131.17
g/l
—
6
18
8
35
2.41
1.30
1.5
1.5
—
—
—
0
0
6
25
2.50
1.26
2.5
2.1
—
—
—
0
0
6
25
2.50
1.26
2.8
2.2
—
—
—
0
0
47
373
1.54
1.19
3.6
2.9
—
—
estimate
—
0
0
5
20
2.58
1.16
1.2
1.5
—
—
—
0
0
15
89
1.82
1.16
9.3
7.6
—
—
—
0
0
13
75
1.86
1.09
2.2
1.4
—
—
—
0
0
24
166
1.61
1.09
2.4
2.7
—
—
—
0
0
14
84
1.79
1.05
3.1
3.1
5.93
5.65
kpa
0.56
14
84
33
253
1.48
0.94
10.2
4.1
4.72
11.57
mg/mmol
1.46
25
155
6
28
2.22
0.93
1.2
1.2
—
—
—
0
0
26
194
1.48
0.84
1.3
1.3
0.57
0.85
u/ml
—
7
47
43
357
1.39
0.77
2.4
2.0
93.57
96.86
pmol/l
0.19
20
170
82
765
1.73
0.77
40.4
19.8
3.91
3.97
mmol/l
1.53
82
750
5
24
2.14
0.76
1.2
1.2
—
—
—
0
0
7
44
1.64
0.67
2.7
2.9
25.00
24.49
mmol/l
—
7
44
0
20
0.00
0.61
0.0
1.5
—
1.14
—
0
14
0
20
0.00
0.61
0.0
1.6
—
1.14
—
0
14
0
20
0.00
0.61
0.0
1.6
—
1.04
—
0
14
54
482
1.30
0.53
4.2
3.1
—
—
—
0
0
81
767
1.51
0.53
40.2
19.8
139.53
139.73
mmol/l
0.30
81
753
25
204
1.31
0.47
6.6
3.6
1.02
1.02
kg/l
0.17
17
134
12
86
1.46
0.47
3.3
2.4
—
—
—
0
0
56
510
1.25
0.43
4.8
3.3
65.22
50.20
u/l
0.68
51
484
26
218
1.27
0.40
5.6
5.4
2.82
1.92
ug/l
0.62
21
192
12
93
1.33
0.32
3.9
2.7
—
—
—
0
0
18
149
1.26
0.31
1.7
1.6
—
—
—
0
0
11
85
1.33
0.29
3.5
2.9
3.08
1.93
mmol/l
0.43
11
70
5
38
1.33
0.23
1.4
1.3
27.30
24.35
iu/l
—
5
33
11
134
0.80
0.22
1.2
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
5.9
—
148.31
—
0
12
73
708
1.16
0.16
4.7
4.3
1.45
1.28
mmol/l
1.02
67
649
19
172
1.13
0.12
4.5
4.6
18.02
21.43
%
0.43
11
89
76
745
1.12
0.09
6.4
5.0
5.84
5.97
mmol/l
0.36
71
681
35
333
1.08
0.09
1.9
2.0
1.31
1.30
mmol/l
0.02
30
280
6
56
1.08
0.09
3.3
2.1
12.37
12.39
nmol/l
—
6
51
0
5
0.00
0.00
0.0
2.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
105.40
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.87
-0.00
1.8
2.6
—
—
—
0
0
83
822
1.11
-0.00
60.5
24.5
130.02
133.92
g/l
2.24
83
817
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
83
821
1.12
-0.00
60.2
25.0
39.57
39.98
%
0.51
83
816
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
3.36
—
0
7
83
821
1.12
-0.00
59.9
24.3
91.89
91.34
fl
0.53
83
816
0
8
0.00
-0.00
0.0
2.0
—
7.53
—
0
8
0
6
0.00
-0.00
0.0
2.3
—
301.17
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
26.41
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint M13_POYARTOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.789 [2.0, 3.89] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.129 |
During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 272 females with M13_POYARTOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_POYARTOTH | 2.272 [1.53, 3.36] | < 0.001 |
| Birth year | 0.986 [0.97, 1.0] | 0.026 |
During the follow-up period (1.1.1998 — 31.12.2019), 72 out of 194 males with M13_POYARTOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_POYARTOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.244% | 0.365% |
| 5 | 1.567% | 2.344% |
| 10 | 4.319% | 5.549% |
| 15 | 7.846% | 11.556% |
| 20 | 13.131% | 19.031% |
Relationships between endpoints
↥Index endpoint: M13_POYARTOTH – Other conditions related to polyarteritis nodosa
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data